Evidence map›Paper›PMID 36684595›Full record

ArticleFrontiers in cardiovascular medicine2022

Impact of different guidewires on the implantation depth using the largest self-expandable TAVI device.

Verena Veulemans, Nihal Wilde, Hendrik Wienemann, Rik Adrichem, Thijmen W Hokken, Baravan Al-Kassou, Jasmin Shamekhi, Victor Mauri, Oliver Maier, Christian Jung and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Verena VeulemansDepartment of Cardiology, Pulmonology, and Vascular Diseases, University Hospital Düsseldorf, Düsseldorf, Germany.
Nihal WildeDepartment of Medicine II, Heart Center, University Hospital Bonn, Bonn, Germany.
Hendrik WienemannDepartment of Cardiology, Heart Center, University of Cologne, Cologne, Germany.
Rik AdrichemDepartment of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands.
Thijmen W HokkenDepartment of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands.
Baravan Al-KassouDepartment of Medicine II, Heart Center, University Hospital Bonn, Bonn, Germany.
Jasmin ShamekhiDepartment of Medicine II, Heart Center, University Hospital Bonn, Bonn, Germany.
Victor MauriDepartment of Cardiology, Heart Center, University of Cologne, Cologne, Germany.
Oliver MaierDepartment of Cardiology, Pulmonology, and Vascular Diseases, University Hospital Düsseldorf, Düsseldorf, Germany.
Christian JungDepartment of Cardiology, Pulmonology, and Vascular Diseases, University Hospital Düsseldorf, Düsseldorf, Germany.
Patrick HornDepartment of Cardiology, Pulmonology, and Vascular Diseases, University Hospital Düsseldorf, Düsseldorf, Germany.
Matti AdamDepartment of Cardiology, Heart Center, University of Cologne, Cologne, Germany.
Georg NickenigDepartment of Medicine II, Heart Center, University Hospital Bonn, Bonn, Germany.
Stephan BaldusDepartment of Cardiology, Heart Center, University of Cologne, Cologne, Germany.
Nicolas M Van MieghemDepartment of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands.
Malte KelmDepartment of Cardiology, Pulmonology, and Vascular Diseases, University Hospital Düsseldorf, Düsseldorf, Germany.
Alexander SedaghatDepartment of Medicine II, Heart Center, University Hospital Bonn, Bonn, Germany.
Tobias ZeusDepartment of Cardiology, Pulmonology, and Vascular Diseases, University Hospital Düsseldorf, Düsseldorf, Germany.
University Hospital Bonn · DEDüsseldorf University Hospital · DEErasmus MC · NLUniversity Hospital Cologne · DEHeinrich Heine University Düsseldorf · DEUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The deployment process of the largest self-expandable device (STHV-34) during transcatheter aortic valve implantation (TAVI) might be challenging due to stabilization issues. Whether the use of different TAVI-guidewires impact the procedural success and outcome is not well-known. Therefore, we sought to evaluate the impact of non-Lunderquist (NLu) vs. the Lunderquist (Lu) guidewires during TAVI using the STHV-34 on the procedural and 30-day outcomes. Methods: The primary study endpoint was defined as the final implantation depth (ID) depending on the selected guidewire strategy. Key secondary endpoints included VARC-3-defined complications. Results: The study cohort included 398 patients of four tertiary care institutions, of whom 79.6% (317/398) had undergone TAVI using NLu and 20.4% (81/398) using Lu guidewires. Baseline characteristics did not substantially differ between NLu and Lu patients. The average ID was higher in the Lu cohort (NLu vs. Lu: -5.2 [-7.0-(-3.5)] vs. -4.5 [-6.0-(-3.0)]; Conclusion: The use of the Lunderquist

Indexed as

complicationselderlyimplantation depthoutcomeTAVI

Identifiers

PMID36684595
PMCPMC9849574
OpenAlexW4313558878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.